TP53 and non-small cell lung carcinoma: found that cisplatin treatment increased STING and PD-L1 expression in tumor tissues, and further found that STING expression was associated with gene mutation status, with lower levels of STING expression in NSCLC with STK11 mutations and high levels of STING and immune-related gene in NSCLC with TP53 mutations expression (12).